Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

[VUBot]

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.…

#glp1 #novonordiskavnyse #nvo #semaglutide #elilillyco #lly #wegovy #fda #mounjaro #bmi

Continue reading...